Trials / Unknown
UnknownNCT00903578
Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients
Impact of FGF-23 and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Ramathibodi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality at 5 years.
Conditions
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2009-05-18
- Last updated
- 2009-12-17
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT00903578. Inclusion in this directory is not an endorsement.